Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Gerald G. Gross"'
Autor:
Hao Xie, Jacqueline M. Lafky, Bruce W. Morlan, Philip J. Stella, Shaker R. Dakhil, Gerald G. Gross, William S. Loui, Joleen M. Hubbard, Steven R. Alberts, Axel Grothey
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been im
Externí odkaz:
https://doaj.org/article/a68f44c6d5e44ed1866977c2a7898ead
Autor:
Kostandinos Sideras, David W Hillman, Karthik Giridhar, Brenda F Ginos, Richard C Tenglin, Heshan Liu, Beiyun Chen, Winston Tan, Gerald G Gross, Rex B Mowat, Amylou C Dueck, Edith A Perez, Alvaro Moreno-Aspitia
Publikováno v:
The oncologist.
Background Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel aza-anthracenedione with structural similarities to mitoxantrone and anthracyclines, is theorized
Autor:
Jacqueline M. Lafky, Gerald G. Gross, Philip J. Stella, William S. Loui, Joleen M. Hubbard, Hao Xie, Axel Grothey, Bruce W. Morlan, Steven R. Alberts, Shaker R. Dakhil
Publikováno v:
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC). Activation of alternative angiogenesis pathways has been im
Autor:
Robert J. Behrens, Mark D. Sborov, Heidi Mc Kean, Eliot L Friedman Md, Shauna L. Hillman, Kendrith M. Rowland, Gerald G. Gross, Michael W. Cannon, Philip J. Stella, Aminah Jatoi
How do oncologists choose therapy for the elderly? Oncologists assigned patients aged 65 years or older with incurable non-small cell lung cancer to: (a) carboplatin (AUC = 2) + paclitaxel 50 mg/m(2) days 1, 8, 15 (28-day cycle × 4) followed by gefi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1cdfa186875999da6730e4d7e9de471
https://europepmc.org/articles/PMC5585010/
https://europepmc.org/articles/PMC5585010/
Autor:
Kevin C. Halling, Beiyun Chen, Rex B. Mowat, Edith A. Perez, Gerald G. Gross, Alvaro Moreno-Aspitia, Wilma L. Lingle, Kostandinos Sideras, Richard Charles Tenglin, Heshan Liu, Shaker R. Dakhil, Monica M. Reinholz
Publikováno v:
Journal of Clinical Oncology. 30:1083-1083
1083 Background: Pixantrone (Pix) is a novel aza-anthracenedione with structural similarities to mitoxantrone and promising activity against non-Hodgkin’s lymphoma. Due to the lack of iron binding it is theorized to exhibit less cardiotoxicity than
Autor:
Kempin S; Beth Israel Comprehensive Cancer Center, New York, New York, USA, skmd3@aol.com., Sun Z; Dana Farber Cancer Institute-ECOG-ACRIN Biostatistics Center, Boston, Massachusetts, USA., Kay NE; Mayo Clinic, Rochester, Minnesota, USA., Paietta EM; Montefiore Medical Center, Bronx, New York, USA., Mazza JJ; Marshfield Clinic, Marshfield, Wisconsin, USA., Ketterling RP; Mayo Clinic, Rochester, Minnesota, USA., Frankfurt O; Northwestern University, Chicago, Illinois, USA., Claxton DF; Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA., Saltzman JN; University Hospitals of Cleveland, Cleveland, Ohio, USA., Srkalovic G; Sparrow Herbert-Herman Cancer Center, Lansing, Michigan, USA., Callander NS; University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA., Gross G; Sanford Medical Center, Fargo, North Dakota, USA., Tallman MS; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Publikováno v:
Acta haematologica [Acta Haematol] 2019; Vol. 142 (4), pp. 224-232. Date of Electronic Publication: 2019 Jul 23.